26 citations
,
July 1992 in “International Journal of Dermatology” Oral cyclosporine A and prednisolone effectively improved alopecia universalis without side effects.
April 2026 in “Dermatology and Therapy” TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.
10 citations
,
December 2015 in “International Journal of Molecular Sciences” PDCD4 is important for controlling skin cell growth and healing.
20 citations
,
May 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Etanercept effectively treated a severe skin condition when other treatments failed.
November 2018 in “Journal of Investigative Dermatology” Lichen Planopilaris causes irreversible hair loss due to immune attacks on hair stem cells, but modulating PPAR-γ might help treat it.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
13 citations
,
June 2020 in “International Journal of Dermatology” A rare scalp condition mainly in older women can be treated with various alternatives to steroids, which may have fewer side effects.
29 citations
,
March 1983 in “Journal of The American Academy of Dermatology” New treatments for psoriasis have improved effectiveness and may reduce long-term side effects when combined with standard therapies.
January 2024 in “Brazilian Journal of Hair Health” Combining low-level laser therapy with topical corticosteroids effectively improved Lichen Planopilaris symptoms.
1 citations
,
July 2015 in “British Journal of Dermatology” Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
November 2025 in “Journal of Investigative Dermatology” Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.
June 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” Platelet-rich Plasma Gel may help treat en coup de sabre scleroderma, improving symptoms and skin quality with minimal side effects.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Erosive pustular dermatosis of the scalp can occur about 17 weeks after starting EGFR inhibitors, and early minocycline may help manage it.
1 citations
,
October 2025 in “Nano Research” A new microneedle patch effectively treats atopic dermatitis by reducing skin stress and restoring immune balance.
April 2023 in “Journal of Investigative Dermatology” Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.
28 citations
,
December 2011 in “Biocatalysis and biotransformation” PDI helps restore over-bleached hair's strength and structure by attaching special peptides.
July 2023 in “International journal of trichology” Injectable platelet-rich fibrin may stop hair loss from Discoid lupus erythematosus.
18 citations
,
September 2016 in “International Journal of Molecular Sciences” Polydeoxyribonucleotide (PDRN) may help lighten skin and treat hyperpigmentation.
12 citations
,
January 1987 in “Carcinogenesis” TCDD changes skin cell growth and keratin production in mice.
2 citations
,
April 2012 in “Science-business Exchange” Blocking a protein called prostaglandin D2 might help treat hair loss.
May 2025 in “Galen Medical Journal” New targeted therapies for psoriasis show promise but face challenges like side effects and treatment resistance.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
15 citations
,
June 2019 in “Biochemical Journal” A new genetic disorder caused by an ODC1 mutation can be treated with DFMO.
3 citations
,
July 2021 in “Cutis” Panniculitis in dermatomyositis is rare, more common in women, and may persist despite treatment.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
January 2016 in “프로그램북(구 초록집)” The thulium laser and PDRN injections effectively improved hair thickness in patients with pattern hair loss.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.